21.01.2025 • NewsAzotyGrupa AzotyOrlen

Grupa Azoty Nears Sale of Polyolefins Business to Orlen

Grupa Azoty and Orlen have agreed to continue to work on the terms of a potential transaction whereby Orlen – or another entity designated by Orlen – would acquire all or a portion of the shares currently held by Grupa Azoty in Grupa Azoty Polyolefins or otherwise execute the investment.

The companies said that negotiations on the terms of the deal, as well as an analysis of the potential transaction including due diligence, are scheduled to be finalized by Mar. 31, 2025.

“Since December, based on the signed cooperation agreement and the earlier letter of intent, we have been working intensively on potential solutions for the future of Grupa Azoty Polyolefins. As a result, we can now unequivocally confirm our chosen direction, which is to sell all or part of Polyolefins’ shares held by Grupa Azoty. At this stage, we will begin due diligence and seek to negotiate the terms of a potential transaction,” said Adam Leszkiewicz, president of Grupa Azoty’s management board.

“At Grupa Azoty, we believe that this collaboration can bring mutual benefits. From our perspective, a potential transaction is one of the key elements of our ongoing Recovery Program, under which we are developing a new business model for the group,” Leszkiewicz added.

In September 2024, Orlen and Grupa Azoty announced their talks about a strategic analysis of potential transactions in the polymers segment.

© Pressmaster/Shutterstock
© Pressmaster/Shutterstock

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read